



31 August 2023

**ASX ANNOUNCEMENT**

**Appendix 4E – Financial year ended 30 June 2023**

ImpediMed Limited (ASX: IPD) provides the attached Appendix 4E – Preliminary Final Report for the financial year ended 30 June 2023.

**Authorised for release by the Board of ImpediMed Limited.**

**Contact Details**

**Investor Relations Contact:**

Hannah Howlett  
WE Communications  
T: +61 450 648 064

[E: hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

[E: investorrelations@impedimed.com](mailto:investorrelations@impedimed.com)

**About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO<sup>®</sup> Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines<sup>®</sup>) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex<sup>®</sup>, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

**ImpediMed Limited - Appendix 4E**  
**ABN 65 089 705 144**  
**Preliminary final report**

**1** Current Financial Period Ended: 30 June 2023  
 Previous Corresponding Reporting Period: 30 June 2022

The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2023 ("2023 Annual Report") and any public announcements made by ImpediMed Limited and its controlled entities during the year in accordance with continuous disclosure obligations arising under the ASX Listing Rules. Certain prior year amounts have been reclassified for consistency with the current reporting period presentation.

**2 Results for announcement to the market**

	Current reporting period \$000	Previous corresponding period \$000
<b>2.1 Revenue from ordinary activities</b>	<b>\$ 11,344</b>	<b>\$ 10,566</b>
Increase in revenue (\$000):		\$ 778
Percentage increase:		7%
Note: Revenue related to goods and services for the year ended 30 June 2023 was \$11.3 million (2022 \$10.6 million). Within the Medical Segment, the SOZO Core Business revenue was \$8.5 million (2022: \$6.6 million), SOZO Clinical Business was \$2.0 million (2022: \$3.3) and Legacy Revenue was \$0.7 million (2022: \$0.6 million).		
Core Business SOZO revenue totaled \$8.5 million (30 June 2022: \$6.6 million), a 30% total increase over the previous corresponding period. Of the \$8.5 million, SaaS and recurring revenue totaled \$7.3 million (30 June 2022: \$5.5 million), an increase of 33%.		
<b>2.2 (Loss) from ordinary activities after tax attributable to members</b>	<b>(20,521)</b>	<b>(19,874)</b>
Increase in loss from ordinary activities after tax attributable to members (\$000):		\$ 647
Percentage increase:		3%
Note: Refer to the Directors' Report for a detailed analysis.		
<b>2.3 Net (loss) for the period attributable to members</b>	<b>(20,521)</b>	<b>(19,874)</b>
Increase in net loss for the period attributable to members (\$000):		\$ 647
Percentage increase:		3%
Note: Refer to 2.2 above and to the Directors' Report in the 2023 Annual Report.		

**3 Dividends**

**3.1 Dividends** **Nil**

There were no dividends declared and paid during the reporting period on ordinary shares.  
 There were no dividends proposed and not yet recognised as a liability during the reporting period.

**3.2 Dividend Record Date** **Not applicable**

For personal use only

<b>4 Financial Statements</b>		
<b>4.1 Statement of comprehensive income</b> Refer to the Consolidated Statement of Comprehensive Income in the 2023 Annual Report.		
<b>4.2 Statement of financial position</b> Refer to the Consolidated Balance Sheet in the 2023 Annual Report.		
<b>4.3 Statement of cash flows</b> Refer to the Consolidated Cash Flow Statement in the 2023 Annual Report.		
<b>4.4 Statement of retained earnings</b> Refer to the Statement of Changes in Equity in the 2023 Financial Report for movements in retained earnings.		
<b>5 Net tangible assets per security</b>		
	Current reporting period	Previous corresponding period
5.1 Net tangible assets (\$000)	46,107	39,678
Issued share capital at reporting date (\$000)	336,087	307,557
	Current reporting period	Previous corresponding period
Number of shares on issue at reporting date	2,017,968,175	1,777,967,235
<b>Net tangible assets per security</b>	<b>\$ 0.02</b>	<b>\$ 0.02</b>
<b>6 Earnings per security (EPS)</b>		
	Current reporting period	Previous corresponding period
6.1 Weighted average number of ordinary shares (excluding reserved shares) for basic earnings per share (EPS)	1,800,348,506	1,678,954,154
<b>(Loss) per share from continued operations</b>		
<b>Basic EPS</b>	<b>\$ (0.01)</b>	<b>\$ (0.01)</b>
<b>(Loss) per share from profit attributable to ordinary shares</b>		
<b>Basic EPS</b>	<b>\$ (0.01)</b>	<b>\$ (0.01)</b>
Diluted earnings per share has been determined to be the same as basic earnings per share as the actual calculation is anti-dilutive for both periods presented.		
Refer to <i>Note 2 - Earnings per Share</i> in the 2023 Annual Report for additional information pertaining to EPS for the current reporting period.		
<b>7 Acquisitions and divestments</b> Not applicable.		
<b>8 Foreign entities</b> Not applicable.		
<b>9 Associates and joint ventures</b> Not applicable.		
<b>10 Commentary on results for the financial year</b> Refer to the 2023 Annual Report for the year ended 30 June 2023.		
<b>11 Results of segments</b> Refer to <i>Note 4 - Segment Reporting</i> in the 2023 Annual Report for additional information pertaining to segment results for the current reporting period.		
<b>12 Audited Report</b> The report is based on audited accounts which are not subject to dispute, modification, or qualification.		

For personal use only